LONDON, August 18, 2014 /PRNewswire/ --
On Friday, August 15, 2014, the NASDAQ Composite ended at 4,464.93, up 0.27%, the Dow Jones Industrial Average finished the day 0.30% lower at 16,662.91, and the S&P 500 closed at 1,955.06, down 0.01%. During the session six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 716.21, up 0.11%, and the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), Array BioPharma Inc. (NASDAQ: ARRY), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Pharmacyclics Inc. (NASDAQ: PCYC). Free research on these five companies can be accessed at:
On Friday, Alkermes PLC's stock recorded a trading volume of 0.86 million shares, above its three months average volume of 0.74 million shares. The stock finished the day at $42.95, down 1.06%, and registered an intraday range of $42.24 and $43.80. Alkermes PLC's shares have declined 3.24% in the last one month and 1.47% in the past three months. However, the stock has advanced 5.63% on YTD basis. Furthermore, the stock is trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $46.59 is above its 200-day moving average of $44.86. Additionally, shares of Alkermes PLC have a Relative Strength Index (RSI) of 43.28. Sign up and read the free notes on ALKS at:
Amarin Corp. PLC's stock fell by 1.09%, to close Friday's session at $1.82, after oscillating between $1.77 and $1.87. The stock recorded a trading volume of 3.05 million shares, above its three months average volume of 1.99 million shares. Over the last one month and past three months, Amarin Corp. PLC's shares have surged 22.15% and 33.33%, respectively. However, from the beginning of 2014, the stock has lost 7.61%. The company's shares are trading above their 50-day and 200-day moving averages. The stock's 200-day moving average of $1.70 is above its 50-day moving average of $1.61. Further, Amarin Corp. PLC's stock has an RSI of 63.73. The complimentary notes on AMRN can be downloaded as in PDF format at:
On Friday, Array BioPharma Inc.'s stock finished the session 1.04% higher at $3.87. A total of 0.95 million shares were traded, which was below its three months average volume of 1.64 million shares. The stock moved between $3.77 and $3.97 during the session. Over the last one month, Array BioPharma Inc.'s shares have gained 4.88%. However, the stock has fallen by 3.73% over the past three months and 22.75% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.65 is greater than its 50-day moving average of $4.18. Shares of Array BioPharma Inc. have an RSI of 43.87. Register for free on Investor-Edge and access the latest research on ARRY at:
Shares in Navidea Biopharmaceuticals Inc. fluctuated between $1.25 and $1.31 before ending Friday's session up 0.79%, at $1.27. The stock reported a trading volume of 0.32 million shares, below its three months average volume of 0.90 million shares. Further, shares of Navidea Biopharmaceuticals Inc. have lost 3.79% over the last one month. Also, the stock has plummeted 9.29% over the past three months and 38.65% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $1.70 is greater than its 50-day moving average of $1.44. Moreover, shares of Navidea Biopharmaceuticals Inc. have an RSI of 43.01. The complete research on NAVB is available for free at:
Pharmacyclics Inc.'s stock declined 1.54%, to close Friday's session at $122.26, after vacillating between $120.50 and $125.65. The stock recorded a trading volume of 0.72 million shares, below its three months average volume of 1.17 million shares. Over the last one month, Pharmacyclics Inc.'s shares have gained 33.62%. Moreover, over the past three months and from the beginning of 2014, the stock has surged 24.73% and 15.58%, respectively. The company's shares are trading above their 50-day and 200-day moving averages. The stock's 200-day moving average of $112.13 is above its 50-day moving average of $101.95. Further, Pharmacyclics Inc.'s stock traded at a PE ratio of 110.14 and has an RSI of 66.39. Free in depth research on PCYC is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.